Saturday, March 28, 2015: 2:00 PM-3:00 PM
International Ballroom (Hilton Chicago)
Description: The Scientific Plenary III session will consist of presentations on state-of-the-art approaches to prevention and treatment of ovarian cancer in women with germline or somatic defects in the homologous recombination DNA repair pathway (e.g., BRCA1/2). In addition to discussion of novel next-generation DNA sequencing approaches to screening for mutations in this family of genes, data from several clinical trials based on PARP inhibition will be presented.
Moderators: David M. O'Malley, MD, The Ohio State University, James Cancer Hospital, Columbus, OH and Jeff Boyd, PhD, Fox Chase Cancer Center, Philadelphia, PA
2:00 PM
Remarks of an introductory nature
J. Boyd1 and D. M. O'Malley2
1Fox Chase Cancer Center, Philadelphia, PA, 2The Ohio State University, James Cancer Hospital, Columbus, OH
2:17 PM
The genetic basis of ovarian cancer
G. Mitchell
BC Cancer Agency, Vancouver, BC, Canada
2:23 PM
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy
U. A. Matulonis1, P. Harter2, C. Gourley3, M. Friedlander4, I. B. Vergote5, G. J. S. Rustin6, A. Fielding7, S. Spencer7, D. Parry7 and J. A. Ledermann8
1Dana-Farber Cancer Institute, Boston, MA, 2Kliniken Essen-Mitte, Essen, Germany, 3University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom, 4Prince of Wales Cancer Centre, Randwick, Sydney, Australia, 5University Hospital Leuven, Leuven, Belgium, 6Mount Vernon Hospital, Middlesex, United Kingdom, 7AstraZeneca, Macclesfield, United Kingdom, 8University College London, London, United Kingdom
2:33 PM
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study sub-analysis
U. A. Matulonis1, R. T. Penson2, S. M. Domchek3, B. Kaufman4, M. W. Audeh5, S. B. Kaye6, L. R. Molife6, H. Mann7, J. Robertson7 and R. L. Coleman8
1Dana-Farber Cancer Institute, Boston, MA, 2Massachusetts General Hospital/Harvard University, Boston, MA, 3Basser Research Center and Abramson Cancer Center, Philadelphia, PA, 4Sheba Medical Center, Tel Hashomer, Israel, 5Samuel Oschin Cancer Institute, Los Angeles, CA, 6The Royal Marsden Hopital, London, United Kingdom, 7AstraZeneca, Macclesfield, United Kingdom, 8The University of Texas MD Anderson Cancer Center, Houston, TX
2:53 PM
Parp Inhibitor Therapy: Therapeutic Development and Potential in Ovarian Cancer
E. M. Swisher
University of Washington, Seattle, WA
